Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., July 05, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on July 1, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to two new employees of non-statutory stock options to purchase up to a total of 120,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing rule 5635(c)(4).
2024年7月5日，北卡羅來納州達勒姆 - Chimerix (納斯達克:CMRX) 今日宣佈，Chimerix 董事會補償委員會於2024年7月1日授予兩名新員工期權，購買Chimerix普通股的股票期權總數爲120,000股。Chimerix董事會的補償委員會根據納斯達克規定5635(c)(4)規定批准了此項獎勵，視此爲吸引新員工就職的重要因素。
The stock options have an exercise price per share equal to Chimerix's closing trading price as of the grant date. The stock options have a 10-year term and will vest over four years, with one-fourth vesting on the one-year anniversary of the date of hire and the remaining three-fourths vesting over the following three years in equal monthly installments. The stock options are subject to the terms of Chimerix's 2024 Equity Incentive Plan but were granted outside of the 2024 Equity Incentive Plan.
這些期權的每股行使價格等於授予日期的Chimerix收盤交易價格。這些期權有10年的有效期，分四年內分配，第一年的1/4在入職一年週年時分配，其餘3/4平均分配在接下來的三年內。這些期權受限於Chimerix 2024年股權激勵計劃的條款，但是是在其之外授予的。
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company's most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.
Chimerix是一家生物製藥公司，旨在開發有意義地改善和延長面對致命疾病的患者生命的藥物。該公司最先進的臨床階段開發項目ONC201正在開發治療的H3K27M突變性膠質瘤。
CONTACTS:
Will O'Connor
Stern Investor Relations
212-362-1200
ir@chimerix.com
will@sternir.com
聯繫方式：
威爾·奧康納
Stern Investor Relations
212-362-1200
ir@chimerix.com
will@sternir.com
Source: Chimerix, Inc.
來源：錘子醫藥股份有限公司。